会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • FK-506 cytosolic binding protein
    • FK-506胞质结合蛋白
    • US5109112A
    • 1992-04-28
    • US548429
    • 1990-07-05
    • John J. SiekierkaHsuen-Yun HungMarie J. StaruchNolan H. SigalRichard A. Mumford
    • John J. SiekierkaHsuen-Yun HungMarie J. StaruchNolan H. SigalRichard A. Mumford
    • C12N9/90C12N15/90
    • C12N15/90C12N9/90Y10S530/81Y10S530/827
    • A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N-Gly-Val-Gln-Val-Glu-Thr-Ile-Ser-Pro- Gly-Asp-Gly-Arg-Thr-Phe-Pro-Lys- Ar g-Gly-Gln-Thr-X-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Gly-Lys-Lys-Phe-Asp (wherein X is undefined). The HCB protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g., Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyzes the cis-trans isomerization of proline-containing peptide bonds.
    • 具有约26μgFK-506 / mg蛋白的特异性结合活性和约10-12千道尔顿分子量的新的均匀胞质结合(HCB)蛋白可逆地结合免疫抑制剂FK-506而不是环孢菌素A(CSA )。 蛋白质在56℃下加热稳定30分钟,保持其FK-506结合亲和力,并具有(部分)氨基末端氨基酸序列:H2N-Gly-Val-Gln-Val-Glu-Thr-Ile- Ser-Pro-Gly-Asp-Gly-Arg-Thr-Phe-Pro-Lys-Ar g-Gly-Gln-Thr-X-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp -Gly-Lys-Lys-Ph e-Asp(其中X未定义)。 HCB蛋白从哺乳动物组织的细胞溶质中分离,优选人类肿瘤T细胞系,例如Jurkat,并且可用于涉及FK-506大环内酯型免疫抑制剂的诊断和纯化方法。 HCB蛋白还催化含脯氨酸的肽键的顺式 - 反式异构化。